IONS
BEARISH
$75.17
Live
Ionis Pharmaceuticals, Inc. · NASDAQ
Target $97.6
(+29.8%)
$27.57
52W Range
$86.74
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$12.42B
P/E
N/A
ROE
-70.8%
Profit margin
-40.4%
Debt/Equity
5.35
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
IONS presents a significant disconnect between its market valuation and fundamental performance. While the Piotroski F-Score of 5/9 indicates stable financial health, the company is grappling with negative revenue growth (-10.30%) and a severe collapse in YoY EPS (-167.4%). Despite a massive 181% price surge over the last year, the valuation is extreme with a Price/Book of 25.10 and a Price/Sales of 13.16. Heavy insider selling by the CEO and CFO, combined with a bearish technical trend, suggests the current price is driven by speculative pipeline expectations rather than realized value.
Key Strengths
Strong short-term liquidity with a Current Ratio of 3.83
Consistent history of beating earnings estimates (3 of last 4 quarters)
Strong analyst consensus with a target price of $97.60
Significant 1-year price momentum (+181.4%)
Stable Piotroski F-Score (5/9) suggesting no immediate operational collapse
Key Risks
Extreme valuation premiums (P/B 25.10, P/S 13.16)
Negative revenue growth (-10.30% YoY) and declining Q/Q revenue
Severe profitability issues with an operating margin of -105.47%
High leverage with a Debt/Equity ratio of 5.35
Aggressive insider liquidation totaling $45.22M in the last 6 months
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
37
Weak
15
40
75
55
0
AI Verdict
Speculative Overvaluation
Key drivers: Negative revenue growth, Extreme P/B ratio, Insider selling, High Debt/Equity
Confidence
90%
Value
15/100
Graham Number N/A due to negative earnings; stock trades at a massive premium to book value.
Positives
No standout positives identified.
Watchpoints
- P/B of 25.10 is unsustainable
- P/S of 13.16 is high for a shrinking revenue base
- Forward P/E is deeply negative
Future
40/100
Growth metrics are currently negative, contradicting the 'Buy' consensus.
Positives
- High analyst target price ($97.60)
- Strong earnings surprise track record
Watchpoints
- Negative YoY revenue growth
- Crashing EPS growth (-167.4%)
Past
75/100
Historical price action has been bullish, but fundamentals have not kept pace.
Positives
- Exceptional 1-year return (+181.4%)
- Strong 3-year and 5-year price appreciation
Watchpoints
- Recent technical trend is bearish (10/100)
Health
55/100
Liquidity is high, but solvency is pressured by high debt and negative margins.
Positives
- Current Ratio (3.83) and Quick Ratio (3.51) are very strong
- Piotroski F-Score of 5/9 is stable
Watchpoints
- Debt/Equity ratio of 5.35 is high
- Negative ROE (-70.80%)
Dividend
0/100
Typical for biotech, but provides no yield floor for investors.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$75.17
Analyst Target
$97.6
Upside/Downside
+29.8%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for IONS and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
IONS
Ionis Pharmaceuticals, Inc.
Primary
|
+83.9% | +101.9% | +181.4% | +7.4% | +0.5% | +0.5% |
|
ENSG
The Ensign Group, Inc.
Peer
|
+121.6% | +109.3% | +65.7% | +16.2% | -2.4% | +2.3% |
|
JAZZ
Jazz Pharmaceuticals plc
Peer
|
+19.7% | +32.4% | +90.3% | +43.4% | +4.7% | +3.9% |
|
EXEL
Exelixis, Inc.
Peer
|
+91.2% | +119.8% | +29.5% | +14.4% | +4.3% | +0.4% |
|
ALGN
Align Technology, Inc.
Peer
|
-70.6% | -48.8% | +2.3% | +24.8% | -16.9% | -5.6% |
ION
Ionis Pharmaceuticals, Inc.
Primary
5Y
+83.9%
3Y
+101.9%
1Y
+181.4%
6M
+7.4%
1M
+0.5%
1W
+0.5%
ENS
The Ensign Group, Inc.
Peer
5Y
+121.6%
3Y
+109.3%
1Y
+65.7%
6M
+16.2%
1M
-2.4%
1W
+2.3%
JAZ
Jazz Pharmaceuticals plc
Peer
5Y
+19.7%
3Y
+32.4%
1Y
+90.3%
6M
+43.4%
1M
+4.7%
1W
+3.9%
EXE
Exelixis, Inc.
Peer
5Y
+91.2%
3Y
+119.8%
1Y
+29.5%
6M
+14.4%
1M
+4.3%
1W
+0.4%
ALG
Align Technology, Inc.
Peer
5Y
-70.6%
3Y
-48.8%
1Y
+2.3%
6M
+24.8%
1M
-16.9%
1W
-5.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-120.83
PEG Ratio
N/A
P/B Ratio
25.1
P/S Ratio
13.16
EV/Revenue
13.09
EV/EBITDA
-33.45
Market Cap
$12.42B
Profitability
Profit margins and return metrics
Profit Margin
-40.41%
Operating Margin
-105.47%
Gross Margin
1.29%
ROE
-70.8%
ROA
-7.31%
Growth
Revenue and earnings growth rates
Revenue Growth
-10.3%
Earnings Growth
N/A
Q/Q Revenue Growth
-10.26%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
5.35
High debt
Current Ratio
3.83
Strong
Quick Ratio
3.51
Excellent
Cash/Share
$16.23
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
96.1%
Op. Margin
-105.5%
Net Margin
-112.8%
Total Assets
$3.5B
Liabilities
$3.0B
Equity
$0.5B
Debt/Equity
6.20x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.2B
FCF Yield
116%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-25
$-1.15
+5.6% surprise
2025-10-29
$-0.8
+35.1% surprise
2025-07-30
$0.85
+415.1% surprise
Healthcare Sector Comparison
Comparing IONS against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-70.8%
This Stock
vs
-46.09%
Sector Avg
+53.6%
(Excellent)
Profit Margin
-40.41%
This Stock
vs
-19.58%
Sector Avg
+106.4%
(Superior)
Debt to Equity
5.35
This Stock
vs
4.1
Sector Avg
+30.6%
(Higher)
Revenue Growth
-10.3%
This Stock
vs
88.16%
Sector Avg
-111.7%
(Slower)
Current Ratio
3.83
This Stock
vs
3.58
Sector Avg
+6.9%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
IONS
Ionis Pharmaceuticals, Inc.
|
BEARISH | $12.42B | - | -70.8% | -40.4% | $75.17 | |
|
ENSG
The Ensign Group, Inc.
|
NEUTRAL | $11.96B | 34.36 | 16.9% | 6.8% | $204.79 | Compare |
|
JAZZ
Jazz Pharmaceuticals plc
|
NEUTRAL | $11.96B | - | -8.5% | -8.3% | $194.2 | Compare |
|
EXEL
Exelixis, Inc.
|
BULLISH | $11.85B | 15.84 | 35.5% | 33.7% | $44.2 | Compare |
|
ALGN
Align Technology, Inc.
|
NEUTRAL | $11.78B | 29.07 | 10.4% | 10.2% | $164.23 | Compare |
IONS
Ionis...
BEARISH
Mkt Cap
$12.4B
P/E
-
ROE
-70.8%
Price
$75.17
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | DEVERS SHANNON L | Officer | Sale | 6,193 | $458,613 |
| 2026-04-01 | KLEIN JOSEPH S III | Director | Sale | 22,321 | $1,686,302 |
| 2026-04-01 | KLEIN JOSEPH S III | Director | Option Exercise | 22,321 | $880,707 |
| 2026-03-19 | SCHNEIDER EUGENE | Officer | Sale | 5,812 | $412,486 |
| 2026-03-17 | HOUGEN ELIZABETH L | Chief Financial Officer | Sale | 225,220 | $16,313,676 |
| 2026-03-16 | HOUGEN ELIZABETH L | Chief Financial Officer | Option Exercise | 174,999 | $8,989,092 |
| 2026-03-10 | MONIA BRETT P | Chief Executive Officer | Sale | 160,773 | $12,114,155 |
| 2026-03-10 | MONIA BRETT P | Chief Executive Officer | Option Exercise | 148,454 | $9,039,364 |
| 2026-03-10 | JENNE KYLE | Officer | Sale | 37,277 | $2,827,325 |
| 2026-03-10 | JENNE KYLE | Officer | Option Exercise | 37,277 | $1,665,128 |
| 2026-03-09 | O'NEIL PATRICK R | General Counsel | Sale | 10,148 | $763,662 |
| 2026-03-04 | LOSCALZO JOSEPH | Director | Sale | 1,032 | $82,833 |
| 2026-03-04 | LOSCALZO JOSEPH | Director | Option Exercise | 1,032 | $39,278 |
| 2026-03-04 | BAROLDI JOSEPH | Officer | Sale | 6,659 | $530,987 |
| 2026-03-04 | BAROLDI JOSEPH | Officer | Option Exercise | 2,138 | $95,281 |
DEVERS SHANNON L
Officer
2026-04-02
6,193 shares
·
$458,613
KLEIN JOSEPH S III
Director
2026-04-01
22,321 shares
·
$1,686,302
KLEIN JOSEPH S III
Director
2026-04-01
22,321 shares
·
$880,707
SCHNEIDER EUGENE
Officer
2026-03-19
5,812 shares
·
$412,486
HOUGEN ELIZABETH L
Chief Financial Officer
2026-03-17
225,220 shares
·
$16,313,676
HOUGEN ELIZABETH L
Chief Financial Officer
2026-03-16
174,999 shares
·
$8,989,092
MONIA BRETT P
Chief Executive Officer
2026-03-10
160,773 shares
·
$12,114,155
MONIA BRETT P
Chief Executive Officer
2026-03-10
148,454 shares
·
$9,039,364
JENNE KYLE
Officer
2026-03-10
37,277 shares
·
$2,827,325
JENNE KYLE
Officer
2026-03-10
37,277 shares
·
$1,665,128
O'NEIL PATRICK R
General Counsel
2026-03-09
10,148 shares
·
$763,662
LOSCALZO JOSEPH
Director
2026-03-04
1,032 shares
·
$82,833
LOSCALZO JOSEPH
Director
2026-03-04
1,032 shares
·
$39,278
BAROLDI JOSEPH
Officer
2026-03-04
6,659 shares
·
$530,987
BAROLDI JOSEPH
Officer
2026-03-04
2,138 shares
·
$95,281
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
23 analysts
B of A Securities
2026-04-09
Buy
Buy
Barclays
2026-03-26
Overweight
Overweight
Needham
2026-03-25
Buy
Buy
HC Wainwright & Co.
2026-03-25
Buy
Buy
Leerink Partners
2026-03-03
Outperform
Outperform
Piper Sandler
2026-02-27
Overweight
Overweight
Stifel
2026-02-26
Hold
Hold
Needham
2026-02-26
Buy
Buy
Piper Sandler
2026-02-06
Overweight
Overweight
Wells Fargo
2026-01-05
Overweight
Overweight
Past News Coverage
Recent headlines mentioning IONS from our newsroom.
Newest → oldest
No matching news yet.